Limoges Cedex 1, France Clinical Trials

A listing of Limoges Cedex 1, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy …

pd-l1
nivolumab
metastasis
tumor cells
ipilimumab
Clermont Ferrand - CHU
 (89.3 away) Contact site
  • 22 views
  • 25 Jan, 2021
  • +45 other locations
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).

As0010 40021
 (145.7 away) Contact site
  • 27 views
  • 14 Jun, 2021
  • +189 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (1.2 away) Contact site
  • 211 views
  • 02 Jun, 2021
  • +361 other locations
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

Systemic amyloidoses are rare diseases affecting approximately 1 in 100,000 persons each year. In systemic amyloidoses abnormal proteins deposit in bodily organs and severely impair their function, causing death if not treated effectively. Light chain (AL) amyloidosis is caused by a usually small population of plasma cells (the cells that …

Hospital Clinic de Barcelona
 (309.5 away) Contact site
  • 26 views
  • 28 Jan, 2021
  • +7 other locations
Safety Tolerability Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to assess the effects of EYP001a with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

fibrosis
ENYO PHARMA Investigative site 0203
 (1.2 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +34 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

evobrutinib
teriflunomide
aubagio
Reserach Site 451
 (87.7 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +220 other locations
adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion

In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy. Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, …

H pital Bretonneau - CHU Tours
 (110.8 away) Contact site
  • 0 views
  • 16 May, 2021
  • +28 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Polyclinique de Limoges Site Chenieux
 (1.2 away) Contact site
  • 10 views
  • 09 Jun, 2021
  • +207 other locations
Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.

The investigators propose to evaluate premedication with Propofol compared to a control strategy including a placebo with a possible rescue treatment with ketamine to ensure pain control before LISA Procedure . Investigators hypothesize that sedation with Propofol is safe and non-inferior to placebo for the risk of Mechanical Ventilation in …

Chu Limoges
 (1.2 away) Contact site
  • 2 views
  • 23 Jan, 2021
  • +14 other locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

osimertinib
stage iv non-small cell lung cancer
epidermal growth factor receptor
growth factor
measurable disease
CHU de Limoges
 (1.2 away) Contact site
  • 27 views
  • 02 Jun, 2021
  • +307 other locations